The main focus was on changes in visceral fat, while secondary outcomes included body weight, BMI, waist and hip measurements, and blood lipid levels
Queen Square: A History of the National Hospital and its Institute of Neurology Page 56
It is licensed in the UK for adults with obesity (BMI of 30 or above), or overweight adults (BMI of 27 or above) who also have a weight-related health condition
Tirzepatide (Mounjaro, Zepbound) How it works: Combines GLP-1 and GIP hormone mimicking, improving both insulin response and fat metabolism
Lazarus, American Heart Association To view or add a comment, sign in Fibrosis Markers May Help Identify Cardiovascular Risk in Type 2 Diabetes At ADA Scientific Sessions 2026, Dr
Day-to-day coaching, meal planning, and the patient community all live in the app